大麻素受体基因多态性与精神分裂症患者和对照组认知表现的关系。
Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls.
机构信息
Programa Interdisciplinar de Pós-Graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Programa de Pós-Graduação em Genética, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, MG, Brazil.
出版信息
Braz J Psychiatry. 2022 Jan-Feb;44(1):26-34. doi: 10.1590/1516-4446-2020-1650.
OBJECTIVE
To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia.
METHODS
In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS).
RESULTS
We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving.
CONCLUSION
Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.
目的
检验大麻素受体基因变异是否与精神分裂症认知缺陷的病理生理学有关的假说。
方法
在这项遗传关联病例对照研究中，检测了大麻素受体多态性 CNR1 rs12720071 和 CNR2 rs2229579 与 69 名精神分裂症患者和 45 名健康对照者的神经认知功能之间的关联。采用简短认知评估量表（BACS）评估认知功能。
结果
我们发现 CNR1 rs12720071 多态性与患者在几个认知领域的认知表现之间存在一致的关联。C/C 多态性的患者在运动速度、词语流畅性、注意力/加工速度和推理/解决问题方面的表现明显较差。
结论
尽管数据有限，但我们的数据支持 CNR1 变异可能与精神分裂症认知缺陷的发病机制有关的假说。
Zotero 插件